Division of Hematology, Department of Internal Medicine, Ospedale degli Infermi, Biella, Italy.
IOSI Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
Hematol Oncol. 2018 Dec;36(5):757-764. doi: 10.1002/hon.2536. Epub 2018 Aug 16.
The prognostic factors and outcome of 58 acquired immunodeficiency syndrome-related diffuse large B-cell lymphoma (AR-DLBCL) patients from the Swiss HIV Cohort Study, diagnosed from 2004 to 2011, were compared with those of 326 immunocompetent (IC)-DLBCL from the Hematology Division of the Amedeo Avogadro University (Italy) and the Oncology Institute of Southern Switzerland. Median follow-up was 6 years; 5-year overall survival (OS) was 68% (95% CI: 63%-73%) in IC-DLBCL and 63% (95% CI: 49%-75%) in AR-DLBCL (P = .220). The acquired immunodeficiency syndrome-related lymphoma international prognostic index predicted OS in AR-DLBCL. Among 148 patients younger than 61 years (40 AR-DLBCL and 108 IC-DLBCL) treated with RCHOP/RCHOP-like regimens, 20 IC-DLBCL and 9 AR-DLBCL patients died and OS was not significantly different. A higher proportion of early deaths occurred in the AR-DLBCL: indeed, 1-year OS was 94% (95% CI: 87%-97%) in IC-DLBCL and 82% (95% CI: 66%-91%) in AR-DLBCL patients. After rituximab and active antiretroviral therapy introduction, AR-DLBCL and IC-DLBCL patients treated with curative intent have similar long-term survival.
从瑞士艾滋病毒队列研究中比较了 2004 年至 2011 年诊断的 58 例获得性免疫缺陷综合征相关弥漫性大 B 细胞淋巴瘤（AR-DLBCL）患者与来自意大利阿梅迪奥·阿瓦加多大学血液科和瑞士南部肿瘤研究所的 326 例免疫功能正常（IC）-DLBCL 患者的预后因素和结局。中位随访时间为 6 年；IC-DLBCL 的 5 年总生存率（OS）为 68%（95%CI：63%-73%），AR-DLBCL 为 63%（95%CI：49%-75%）（P=.220）。获得性免疫缺陷综合征相关淋巴瘤国际预后指数预测了 AR-DLBCL 的 OS。在接受 RCHOP/RCHOP 样方案治疗的 148 例年龄小于 61 岁的患者中（40 例 AR-DLBCL 和 108 例 IC-DLBCL），20 例 IC-DLBCL 和 9 例 AR-DLBCL 患者死亡，OS 无显著差异。AR-DLBCL 中早期死亡的比例较高：实际上，IC-DLBCL 的 1 年 OS 为 94%（95%CI：87%-97%），AR-DLBCL 为 82%（95%CI：66%-91%）。在利妥昔单抗和积极的抗逆转录病毒治疗引入后，接受根治性治疗的 AR-DLBCL 和 IC-DLBCL 患者具有相似的长期生存。
